{"id":29755,"date":"2024-09-25T16:50:52","date_gmt":"2024-09-25T11:20:52","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=29755"},"modified":"2024-10-10T17:18:01","modified_gmt":"2024-10-10T11:48:01","slug":"prostate-cancer-awareness-month","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month","title":{"rendered":"Prostate Cancer Awareness Month: Early Detection Saves Lives!!"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-69fbead4da3b5\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-69fbead4da3b5\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#What_Is_Prostate_Cancer\" >What Is Prostate Cancer?<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#Prostate_Cancer_Types_and_Stages\" >Prostate Cancer Types and Stages<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#Understanding_Prostate_Cancer_Symptoms\" >Understanding Prostate Cancer Symptoms<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#Who_is_at_Risk_of_Prostate_Cancer\" >Who is at Risk of Prostate Cancer?<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-5\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#The_Importance_of_Early_Detection_and_Awareness_of_Prostate_Cancer\" >The Importance of Early Detection and Awareness of Prostate Cancer<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-6\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#Advances_in_Prostate_Cancer_Treatment_and_Research\" >Advances in Prostate Cancer Treatment and Research<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-7\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#Approved_Drugs_for_Prostate_Cancer_Treatment\" >Approved Drugs for Prostate Cancer Treatment<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-8\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#Emerging_Therapies_for_Prostate_Cancer_Treatment_on_the_Horizon\" >Emerging Therapies for Prostate Cancer Treatment on the Horizon<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-9\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#Prostate_Cancer_Market_Dynamics_and_Trends\" >Prostate Cancer Market Dynamics and Trends<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-10\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#Key_Highlights_from_the_ESMO_2024_and_ASCO_2024_Conferences\" >Key Highlights from the ESMO 2024 and ASCO 2024 Conferences<\/a><ul class='ez-toc-list-level-3' ><li class='ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-11\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#ESMO_2024_Highlights\" >ESMO 2024 Highlights<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-3'><a class=\"ez-toc-link ez-toc-heading-12\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#ASCO_2024_Highlights\" >ASCO 2024 Highlights<\/a><\/li><\/ul><\/li><li class='ez-toc-page-1 ez-toc-heading-level-2'><a class=\"ez-toc-link ez-toc-heading-13\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\/#Final_Thoughts_on_Prostate_Cancer\" >Final Thoughts on Prostate Cancer<\/a><\/li><\/ul><\/nav><\/div>\n\n<p>Every September, the spotlight turns to prostate cancer. Prostate cancer stands as one of the most prevalent cancers among men, affecting approximately <strong>1 in 8 men <\/strong>in the United States during their lifetime. With nearly <strong>288,000 <\/strong>new cases diagnosed each year, men must prioritize regular screenings and early detection. The survival rates for prostate cancer are promising; the five-year survival rate for prostate cancer exceeds <strong>98%<\/strong> when caught early, underscoring the importance of awareness and proactive health measures. Let\u2019s delve into prostate cancer in more detail.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-what-is-prostate-cancer\"><span class=\"ez-toc-section\" id=\"What_Is_Prostate_Cancer\"><\/span><strong>What Is Prostate Cancer?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Prostate cancer is a type of cancer that occurs in the prostate, a small gland located below the bladder in men. This gland produces seminal fluid, which nourishes and transports sperm. Prostate cancer typically develops when cells in the prostate gland begin to grow uncontrollably. This uncontrolled growth can form a tumor, which may remain confined to the prostate or spread to other parts of the body, such as the lymph nodes or bones.<\/p>\n\n\n\n<p>As per DelveInsight\u2019s estimates, the total <a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market-insight\">prevalent population of prostate cancer<\/a> in the 7MM was nearly <strong>8.2 million<\/strong> cases in 2023, however, this figure does not reflect the treatable population. These cases are projected to increase during the forecast period, i.e., 2024\u20132034. The United States had the highest number of prostate cancer cases in 2023.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"388\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171709\/Prostate-Cancer-Key-Facts-1024x388.png\" alt=\"\" class=\"wp-image-29971\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171709\/Prostate-Cancer-Key-Facts-1024x388.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171709\/Prostate-Cancer-Key-Facts-300x114.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171709\/Prostate-Cancer-Key-Facts-150x57.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171709\/Prostate-Cancer-Key-Facts-768x291.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171709\/Prostate-Cancer-Key-Facts-1536x583.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171709\/Prostate-Cancer-Key-Facts.png 1600w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>Based on DelveInsight\u2019s assessment in 2023, the 7MM had approximately <strong>240,300<\/strong> prevalent cases of metastatic prostate cancer. These are expected to rise due to the growing geriatric population and advancements in diagnostic capabilities during the forecast period (2024\u22122034). Around <strong>45%<\/strong> of all metastatic prostate cancer cases are attributed for mCSPC and <strong>~55%<\/strong> accounted for mCRPC.<\/p>\n\n\n\n<p><strong><em>Keen to know more about metastatic prostate cancer? Get all the insights at <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-prostate-cancer-market\"><strong><em>Metastatic Prostate Cancer Market Report<\/em><\/strong><\/a><\/p>\n\n\n\n<p>Prostate cancer is most frequently diagnosed among men aged <strong>65\u201374 years<\/strong>. Analysis indicates that age-specific data differs across various geographic regions. In the US, prostate cancer was least prevalent among individuals aged <strong>over 84 years<\/strong>, whereas in Japan, the lowest number of cases were observed in the age group of <strong>54 years or younger<\/strong>.<\/p>\n\n\n\n<p>Further, DelveInsight\u2019s analysis revealed that in 2023, the US accounted for <strong>1.5 million<\/strong> diagnosed prevalent cases of prostate cancer. These are expected to increase by 2034 owing to increasing aging populations, improved screening methods leading to earlier detection, changes in lifestyle and environmental factors, and advancements in medical technology allowing for better diagnosis and treatment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-prostate-cancer-types-and-stages\"><span class=\"ez-toc-section\" id=\"Prostate_Cancer_Types_and_Stages\"><\/span><strong>Prostate Cancer Types and Stages<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Prostate cancer is primarily categorized into two types: <strong>adenocarcinoma<\/strong>, which accounts for nearly all cases, and <strong>small cell carcinoma<\/strong>, a rare and aggressive form. Adenocarcinoma originates in the glandular cells of the prostate and can vary significantly in behavior. This cancer can be further classified based on its aggressiveness, typically assessed through the Gleason score, which evaluates the pattern of cancer cells under a microscope. Other, less common types include <strong>transitional cell carcinoma and <\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/neuroendocrine-prostate-cancer-market\"><strong>neuroendocrine prostate cancer<\/strong><\/a>, both of which have different characteristics and treatment approaches.<\/p>\n\n\n\n<p>The stages of prostate cancer are determined using the <strong>TNM system<\/strong>, which evaluates the size of the tumor (T), whether the cancer has spread to lymph nodes (N), and whether it has metastasized to distant organs (M). Staging ranges from Stage I, where the cancer is small and localized, to Stage IV, indicating advanced cancer that has spread extensively. Understanding the stage of prostate cancer is crucial for guiding treatment decisions and predicting outcomes. In addition to the TNM classification, the <strong>PSA level (prostate-specific antigen)<\/strong> is often used to help assess the cancer\u2019s status and response to treatment, contributing further to a comprehensive understanding of the disease&#8217;s progression.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-understanding-prostate-cancer-symptoms\"><span class=\"ez-toc-section\" id=\"Understanding_Prostate_Cancer_Symptoms\"><\/span><strong>Understanding Prostate Cancer Symptoms<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Prostate cancer often develops slowly and may not present noticeable symptoms in its early stages. However, as the disease progresses, individuals may experience a variety of signs. Common prostate cancer symptoms include <strong>difficulty urinating<\/strong>, such as a weak or interrupted flow, <strong>frequent urination<\/strong>, especially at night, and a sense of urgency. Some may also experience pain or a <strong>burning sensation during urination<\/strong>. Additionally, prostate cancer can lead to <strong>blood in the urine or semen and painful ejaculation<\/strong>. In advanced stages, it may cause <strong>lower back pain, hip pain, or discomfort in the pelvic area<\/strong>, often due to the spread of cancer to nearby tissues or bones. Early <a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market-and-competitive-landscape\">prostate cancer detection<\/a> and awareness of these prostate cancer symptoms are crucial for effective management and treatment.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-who-is-at-risk-of-prostate-cancer\"><span class=\"ez-toc-section\" id=\"Who_is_at_Risk_of_Prostate_Cancer\"><\/span><strong>Who is at Risk of Prostate Cancer?<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Prostate cancer risk factors are varied and can be categorized into non-modifiable and modifiable factors. Non-modifiable risk factors include <strong>age, race, and family history<\/strong>. The likelihood of developing prostate cancer increases significantly with age, particularly after the <strong>age of 50<\/strong>. Additionally, <strong>men of African descent<\/strong> are at a higher risk compared to their <strong>Caucasian and Asian counterparts<\/strong>. A family history of prostate cancer also raises an individual\u2019s risk, suggesting a genetic predisposition that can contribute to the development of the disease.<\/p>\n\n\n\n<p>Modifiable prostate cancer risk factors, on the other hand, are lifestyle-related and can be influenced by personal choices. Research indicates that obesity is linked to an increased risk of aggressive prostate cancer. Diet plays a critical role as well; a <strong>high intake of red meat and high-fat dairy products<\/strong> may contribute to the risk, while a <strong>diet rich in fruits and vegetables<\/strong> may have a protective effect. Moreover, <strong>physical activity and maintaining a healthy weight<\/strong> are associated with a lower risk of prostate cancer. Understanding these risk factors is essential for men to take preventative measures and make informed health choices.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"446\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130816\/Prostate-Cancer-Symptoms-Risks-and-Diagnosis-1024x446.png\" alt=\"Prostate Cancer Symptoms Risks and Diagnosis\" class=\"wp-image-29762\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130816\/Prostate-Cancer-Symptoms-Risks-and-Diagnosis-1024x446.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130816\/Prostate-Cancer-Symptoms-Risks-and-Diagnosis-300x131.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130816\/Prostate-Cancer-Symptoms-Risks-and-Diagnosis-150x65.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130816\/Prostate-Cancer-Symptoms-Risks-and-Diagnosis-768x335.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130816\/Prostate-Cancer-Symptoms-Risks-and-Diagnosis-1536x669.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130816\/Prostate-Cancer-Symptoms-Risks-and-Diagnosis-2048x893.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-the-importance-of-early-detection-and-awareness-of-prostate-cancer\"><span class=\"ez-toc-section\" id=\"The_Importance_of_Early_Detection_and_Awareness_of_Prostate_Cancer\"><\/span><strong>The Importance of Early Detection and Awareness of Prostate Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Early detection of prostate cancer significantly enhances the likelihood of successful treatment and recovery. When identified in its early stages, prostate cancer is often manageable and can be treated effectively, leading to better survival rates. Regular prostate cancer screenings allow for the detection of the disease before prostate cancer symptoms appear, providing an opportunity for intervention at a stage when treatment options are more varied and less invasive. Moreover, advancements in medical technology and treatment modalities have made it possible to tailor therapies to individual patients, further improving outcomes.&nbsp;<\/p>\n\n\n\n<p>Additionally, awareness also plays a pivotal role in encouraging men to recognize the risk factors and symptoms associated with prostate cancer. Many men are unaware that they are at risk, particularly those over the age of 50, or those with a family history of the disease. By educating men about the importance of regular prostate cancer screenings, such as <strong>prostate-specific antigen (PSA) tests<\/strong> and <strong>digital rectal exams (DRE)<\/strong>, healthcare providers can help facilitate earlier prostate cancer diagnosis and treatment. Increased awareness can also help dispel myths and stigmas surrounding prostate cancer, encouraging men to seek medical advice and support.<\/p>\n\n\n\n<p>Thus, promoting awareness and fostering a proactive approach to screening can save lives and improve the quality of life for those diagnosed with prostate cancer.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-advances-in-prostate-cancer-treatment-and-research\"><span class=\"ez-toc-section\" id=\"Advances_in_Prostate_Cancer_Treatment_and_Research\"><\/span><strong>Advances in Prostate Cancer Treatment and Research<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Prostate cancer treatment has evolved significantly in recent years, offering patients a range of options tailored to the stage and aggressiveness of the disease. The primary treatment modalities include <strong>surgery, radiation therapy, and active surveillance<\/strong>. For localized prostate cancer, radical prostatectomy or radiation therapy is often recommended, aiming to remove or destroy cancer cells while preserving surrounding tissue.<\/p>\n\n\n\n<p><strong>Hormone therapy<\/strong> may sometimes be utilized as well. Patients who have never undergone <strong>androgen deprivation therapy (ADT)<\/strong> and are responsive to it are referred to as having hormone-sensitive prostate cancer (HSPC) or castrate-sensitive prostate cancer (CSPC). The primary <a href=\"https:\/\/www.delveinsight.com\/report-store\/non-metastatic-prostate-cancer-market\">treatments for non-metastatic castration-resistant prostate cancer (nmCRPC)<\/a> include ADT, also known as hormone therapy, second-line ADT, and active surveillance. If the cancer has spread to the bones or other areas beyond the prostate, treatment options may include <strong>pain relief medications, bisphosphonates, RANK ligand inhibitors, hormonal therapy, chemotherapy, radiopharmaceuticals, immunotherapy, focused radiation<\/strong>, and various targeted therapies.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-approved-drugs-for-prostate-cancer-treatment\"><span class=\"ez-toc-section\" id=\"Approved_Drugs_for_Prostate_Cancer_Treatment\"><\/span><strong>Approved Drugs for Prostate Cancer Treatment<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Current therapies for metastatic prostate cancer treatment include <strong>Astella\/Pfizer\u2019s XTANDI <\/strong>and <strong>Janssen\u2019s ZYTIGA<\/strong>, both of which have been on the market for over a decade. Even though ZYTIGA\u2019s generics have entered the US market since 2019 and the EU since late 2022, leading to a drastic decline in the revenue mainly in the US, the product is extensively being evaluated in combination with novel emerging therapies, leading to an increase in patient share on the compound abiraterone acetate.<\/p>\n\n\n\n<p>Janssen expanded its portfolio with the introduction of <strong>ERLEADA <\/strong>in 2019 for mHSPC, following its 2018 approval for nmCRPC. Additionally, <strong>Bayer\u2019s NUBEQA <\/strong>has quickly gained traction and is emerging as a strong competitor.<\/p>\n\n\n\n<p>Moreover, <a href=\"https:\/\/www.delveinsight.com\/report-store\/parp-inhibitors-competitive-landscape-pipeline-and-market-analysis\">PARP inhibitors<\/a> are making their mark in patients with HRR gene mutations (BRCA1\/2). <strong>AstraZeneca\u2019s LYNPARZA<\/strong> was introduced for 1L+ prostate cancer treatment, while <strong>Pharma&amp; Schwiez\u2019s<\/strong> <strong>RUBRACA <\/strong>became available for 3L mCRPC patients in 2020. Notably, in 2023, <strong>Pfizer\u2019s TALZENNA, Janssen Pharmaceuticals\u2019 AKEEGA, and AstraZeneca\/Merck Sharp &amp; Dohme\u2019s LYNPARZA<\/strong> were also approved for use in the first-line setting. Drugs such as <strong>Myovant Sciences\u2019 ORGOVYX and Sanofi\u2019s JEVTANA<\/strong> have also received regulatory approval for mCRPC in the United States.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"430\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171754\/Marketed-Drugs-for-Prostate-Cancer-1024x430.png\" alt=\"\" class=\"wp-image-29973\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171754\/Marketed-Drugs-for-Prostate-Cancer-1024x430.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171754\/Marketed-Drugs-for-Prostate-Cancer-300x126.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171754\/Marketed-Drugs-for-Prostate-Cancer-150x63.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171754\/Marketed-Drugs-for-Prostate-Cancer-768x323.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171754\/Marketed-Drugs-for-Prostate-Cancer-1536x645.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/10\/10171754\/Marketed-Drugs-for-Prostate-Cancer-2048x860.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The mCRPC treatment market saw the approval of <strong>Novartis\u2019 radioligand therapy,<\/strong> <strong>PLUVICTO<\/strong>, in 2022, leading to unexpectedly high revenue in the third-line mCRPC segment. Novartis aims to further extend its reach into earlier-line mCRPC by 2024 and mHSPC by 2025 in the US market.<\/p>\n\n\n\n<p><strong><em>Explore the breakthroughs in <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-castration-resistant-prostate-cancer-mcrpc-market\"><strong><em>mCRPC treatment<\/em><\/strong><\/a><strong><em> \u2013 discover why it\u2019s leading prostate cancer research<\/em><\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-emerging-therapies-for-prostate-cancer-treatment-on-the-horizon\"><span class=\"ez-toc-section\" id=\"Emerging_Therapies_for_Prostate_Cancer_Treatment_on_the_Horizon\"><\/span><strong>Emerging Therapies for Prostate Cancer Treatment on the Horizon<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-pipeline-insight\">prostate cancer pipeline<\/a> possesses some drugs in mid and late-stage developments to be approved in the near future. Quantitatively mCRPC pipeline seems to be quite strong, however with recent failures\/terminations of several trials of certain therapies such as <strong>KEYTRUDA <\/strong>and <strong>OPDIVO<\/strong> in the past year.&nbsp;<\/p>\n\n\n\n<p>As per analysis, some of the potential prostate cancer drugs include <strong>ESSA Pharma\u2019s EPI-7386, Macrogenics\u2019s and Daiichi Sankyo anti-B7-H3 antibody-drug conjugates, MGC-018 and DS-7300, respectively, Arvinas\u2019s AR-targeted PROTAC protein degrader (ARV-766), Point Biopharma\u2019s radioligand therapy (177Lu-PNT2002), Exelixis\u2019s multiple receptor tyrosine kinase (Cabozantinib), <\/strong>and<strong> Promontory Therapeutics\u2019s pyrophosphate conjugate (PT-112)<\/strong>.<\/p>\n\n\n\n<p>Some of the other <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-prostate-cancer-pipeline-insight\">prostate cancer drugs<\/a> in the late stage of development include <strong>177Lu-PSMA-I&amp;T<\/strong> (Curium), <strong>Opevesostat (MK-5684)<\/strong> (Merck and Orion), <strong>177Lu-DOTA-rosopatamab<\/strong> (Telix Pharmaceuticals), <strong>Capivasertib <\/strong>(AstraZeneca), <strong>Masitinib <\/strong>(AB Science), <strong>FPI-2265<\/strong> (Fusion Pharma), <strong>Mevrometostat (PF-06821497)<\/strong> (Pfizer), <strong>Fuzuloparib <\/strong>(Jiangsu Hengrui Pharmaceuticals), <strong>ModraDoc006<\/strong> (Modra Pharmaceuticals), <strong>BMS-986218 <\/strong>(Bristol-Myers Squibb), <strong>Lorigerlimab <\/strong>(MacroGenics), <strong>SX-682 <\/strong>(Syntrix Pharmaceuticals), <strong>ZEN-3694<\/strong> (Zenith Epigenetics), <strong>Vudalimab <\/strong>(Xencor), <strong>Zenocutuzumab <\/strong>(Merus), <strong>Vobramitamab Duocarmazine<\/strong> (MacroGenics), <strong>LAE201 <\/strong>(Laekna Therapeutics), <strong>TAVT-45<\/strong> (Tavanta Therapeutics), <strong>pTVG-HP<\/strong> <strong>(MVI-816)<\/strong> (Madison Vaccines), <strong>TAS-115<\/strong> (Taiho Pharmaceutical), <strong>KPG-121<\/strong> (Kangpu Biopharmaceuticals), and <strong>CAN-2409<\/strong> (Candel Therapeutics).<\/p>\n\n\n\n<p>On the other hand, the <a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-castration-sensitive-prostate-cancer-pipeline-insight\">emerging landscape of mCSPC treatment<\/a> also holds a diverse range of therapeutic alternatives for treatment, including <strong>PLUVICTO <\/strong>(Novartis), <strong>TALZENNA + XTANDI<\/strong> (Pfizer), <strong>Saruparib <\/strong>(AstraZeneca), <strong>TRUQAP + abiraterone<\/strong> (AstraZeneca), <strong>AKEEGA <\/strong>(Niraparib\/abiraterone acetate) + <strong>prednisone <\/strong>(Janssen), <strong>NUBEQA + ADT<\/strong> (Bayer), <strong>ORGOVYX <\/strong>(Myovant Sciences\/Sumitomo Pharma), and others. In addition to these, Jiangsu Hengrui is evaluating <strong>dalpiciclib + abiraterone + prednisone <\/strong>and <strong>SHR3680 <\/strong>for treating mCSPC, in separate prostate cancer clinical trials, in China.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"1024\" height=\"506\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130956\/Key-Companies-in-the-Prostate-Cancer-Therapeutic-Segment-1024x506.png\" alt=\"Key Companies in the Prostate Cancer Therapeutic Segment\" class=\"wp-image-29764\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130956\/Key-Companies-in-the-Prostate-Cancer-Therapeutic-Segment-1024x506.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130956\/Key-Companies-in-the-Prostate-Cancer-Therapeutic-Segment-300x148.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130956\/Key-Companies-in-the-Prostate-Cancer-Therapeutic-Segment-150x74.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130956\/Key-Companies-in-the-Prostate-Cancer-Therapeutic-Segment-768x380.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130956\/Key-Companies-in-the-Prostate-Cancer-Therapeutic-Segment-1536x759.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130956\/Key-Companies-in-the-Prostate-Cancer-Therapeutic-Segment-2048x1012.png 2048w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/figure>\n\n\n\n<p>The expected launch of these prostate cancer therapies shall further create a positive impact on the market.<\/p>\n\n\n\n<p><strong><em>Discover more about mCSPC drugs in development at <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/metastatic-castration-sensitive-prostate-cancer-mcspc-market\"><strong><em>Metastatic Castration-Sensitive Prostate Cancer Clinical Trials<\/em><\/strong><\/a><\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-prostate-cancer-market-dynamics-and-trends\"><span class=\"ez-toc-section\" id=\"Prostate_Cancer_Market_Dynamics_and_Trends\"><\/span><strong>Prostate Cancer Market Dynamics and Trends<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The prostate cancer therapeutic landscape is marked by intense competition, with numerous approved treatments currently available in the market and several promising therapies in the pipeline addressing unmet needs in both conditions.<\/p>\n\n\n\n<p>As per DelveInsight analysis, the total market size of mCRPC in the 7MM in 2023 was approximately <strong>USD 7 billion<\/strong>. On the other hand, the total market size of mCSPC in the 7MM in 2023 was <strong>USD 2.6 billion<\/strong>. This is anticipated to grow by 2034 at a moderate CAGR.<\/p>\n\n\n\n<p>As per the estimates, the US accounted for the largest market size of mCRPC and mCSPC in 2023, i.e., nearly<strong> 66%<\/strong> in comparison to EU4 (Germany, Italy, France, and Spain) and the UK, and Japan. In the current market, <strong>XTANDI <\/strong>accounted for the major share, which was around <strong>USD 2.8 billion<\/strong> in 2023. However, XTANDI sales are expected to decline due to the US Inflation Reduction Act (IRA) impact which is scheduled to be effective Jan 2025.<\/p>\n\n\n\n<p>The <a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market-insight\">prostate cancer market<\/a> is expected to witness significant growth owing to the rising prevalence of prostate cancer cases, the emergence of novel, more accurate, next-generation imaging techniques, extensive market penetration of approved therapies in mCRPC due to label expansions, and the entry of new emerging therapies.&nbsp;<\/p>\n\n\n\n<p>However, challenges such as high treatment costs, regulatory hurdles, and disparities in healthcare access may impact market expansion. Overall, the interplay between these factors is creating a dynamic landscape in the prostate cancer market, offering opportunities for growth while also necessitating strategies to address existing barriers.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-highlights-from-the-esmo-2024-and-asco-2024-conferences\"><span class=\"ez-toc-section\" id=\"Key_Highlights_from_the_ESMO_2024_and_ASCO_2024_Conferences\"><\/span><strong>Key Highlights from the ESMO 2024 and ASCO 2024 Conferences<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>The ASCO and ESMO conferences serve as pivotal platforms for presenting the latest advancements in oncology research including prostate cancer. At these events, researchers and clinicians share groundbreaking data on novel therapies, clinical trial results, and innovative treatment strategies, shaping the future of prostate cancer management.<\/p>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-esmo-2024-highlights\"><span class=\"ez-toc-section\" id=\"ESMO_2024_Highlights\"><\/span><strong>ESMO 2024 Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>The majority of abstracts focus on mCRPC with BMS\u2019 dual androgen receptor (AR) ligand-directed degrader and antagonist in heavily pretreated mCRPC, Bayer\/Astellas\u2019 Phase III trial comparing XTANDI vs XTANDI + XOFIGO&nbsp; in asymptomatic or mildly symptomatic mCRPC, Exelixis\/Ipsen\u2019s overall survival data of Cabozantinib and Atezolizumab combo from pivotal CONTACT-02 trial in mCRPC, whereas, Amgen and Epizyme are coming up with novel classes, a STEAP1 x CD3 XmAb 2+1 Immune Therapy and EZH2 inhibitor respectively in early stages.<\/p>\n\n\n\n<p>Below are the potential prostate cancer data readouts during the ESMO 2024 conference:<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-96b49c39-7fff-9f55-79f0-d8809a25fd6b\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"left\">\n<table style=\"border: none; border-collapse: collapse;\"><colgroup><col width=\"98\" \/><col width=\"110\" \/><col width=\"88\" \/><col width=\"82\" \/><col width=\"118\" \/><col width=\"164\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Drug&nbsp;<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Company<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Abstract No.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Phase<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Abstract Title<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: bold; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Data Readouts<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Radium-223 (Ra223) + enzalutamide<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Bayer\/Astellas<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">LBA1<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">A randomized multicenter open-label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer &nbsp; mCRPC): First results of EORTC-GUCG 1333\/PEACE-3<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; In the Ra223 + enzalutamide arm: The median rPFS of 19.4 months; the median OS in the preplanned interim analysis of 42.3 months&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; No TEAE &ge; grade 3 was increased by more than 5% in the ENZ-RAD arm vs the ENZ arm.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Cabozantinib + atezolizumab<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Exelixis\/Ipsen<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">LBA67<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Cabozantinib (C) Plus Atezolizumab (A) Versus 2nd Novel Hormonal Therapy (NHT) in Patients (Pts) with Metastatic Castration-Resistant Prostate Cancer (mCRPC): Final Overall Survival (OS) Results of the Phase 3, Randomized, CONTACT-02 Study<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; In Cabozantinib + atezolizumab arm:<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">i) Median OS (months): 14.78 (ITTN), 13.80 (BM), 12.19 (LM), 13.37 (prior docetaxel)<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">ii) Median PFS (months): 6.34 (ITTN), 6.31 (BM), 6.24 (LM), 8.84 (prior docetaxel)<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; Treatment-related Grade 3-4 AEs occurred in 40%.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Enzalutamide&nbsp; &plusmn; talazoparib<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Pfizer\/Astellas<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">1601P<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">First results from ZZFIRST: a randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-na&iuml;ve prostate cancer (mHNPC)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; In the Enzalutamide&nbsp; &plusmn; talazoparib arm: Median rPFS was not reached; 2-years rPFS rate was 78.5%<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; Fatigue and anemia were the most common TEAEs.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Tazemetostat + enzalutamide&nbsp;<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Epizyme<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">1603P<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">I\/II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; In the tazemetostat + enzalutamide arm: The median rPFS was 16.6 months; ORR was 8.3%.<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; Grade &ge;3 TEAEs were reported by 46.3%.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">BMS-986365<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Bristol Myers Squibb<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">1597MO<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">I<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Clinical activity of BMS-986365 (CC-94676), a dual androgen receptor (AR) ligand-directed degrader and antagonist, in heavily pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; 48% achieved PSA30 and 32% PSA50; median rPFS was 6.3 months<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; There were no &ge; Grade 4 TRAE or discontinuations due to TRAE.<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Xaluritamig<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Amgen<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">1598P<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">I<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">Xaluritamig, a STEAP1 x CD3 XmAb 2+1 Immune Therapy, in Patients (pts) With Metastatic Castration-Resistant Prostate Cancer (mCRPC): Initial Results From Dose Expansion Cohorts in a Phase 1 Study<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; PSA 50 response confirmed, 29% (0.75 mg QW), 62.1% (1.5 mg QW), 44.8% (1.5 mg Q2W).&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri,sans-serif; color: #000000; background-color: transparent; font-weight: 400; font-style: normal; font-variant: normal; text-decoration: none; vertical-align: baseline; white-space: pre-wrap;\">&#8211; All patients experienced TRAEs. Grade 3 AEs were mostly transient and manageable.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong><em>Get an exclusive <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/esmo-conference-2024\"><strong><em>ESMO 2024 Conference analysis<\/em><\/strong><\/a><strong><em> of all the abstracts presented during the conference<\/em><\/strong><\/p>\n\n\n\n<h3 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"ASCO_2024_Highlights\"><\/span><strong>ASCO 2024 Highlights<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h3>\n\n\n\n<p>Below are the potential prostate cancer data readouts held at the ASCO 2024 conference:<\/p>\n\n\n\n<p><span id=\"docs-internal-guid-96b49c39-7fff-9f55-79f0-d8809a25fd6b\"><\/span><\/p>\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"left\">\n<div dir=\"ltr\" style=\"margin-left: 0pt;\" align=\"left\">\n<table style=\"border: none;\"><colgroup><col width=\"98\" \/><col width=\"110\" \/><col width=\"88\" \/><col width=\"82\" \/><col width=\"118\" \/><col width=\"164\" \/><\/colgroup>\n<tbody>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Drug&nbsp;<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Company<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Abstract No.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Phase<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Abstract Title<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #bfe6ff; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-weight: bold; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Data Readouts<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">177Lu-PSMA-617<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Novartis<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">5003<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Health-related quality of life and pain in a phase 3 study of [177Lu]Lu-PSMA-617 in taxane-na&iuml;ve patients with metastatic castration-resistant prostate cancer (PSMAfore)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Median duration of exposure was 8.4 months<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Lu-PSMA-617 delayed time to worsening in FACT-P and EQ-5D-5L<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&nbsp;Time to quality of life deterioration was longer by about 40%.&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Time to pain deterioration was longer by about 30%<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Survival was similar and is likely confounded by the almost 80% crossover rate among men<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Abemaciclib + abiraterone<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Eli Lilly<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">5001<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">II\/III<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">CYCLONE 2: A phase 3 study of abemaciclib with abiraterone in patients with metastatic castration-resistant prostate cancer.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Median rPFS by investigator: 22 months<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Median rPFS by BICR: 24.9 months<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Median OS: 38 months&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; ORR: 45%; DOR: 21.3 months<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; PSA50 response: 70.4%<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Safety of the combination was consistent<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">ODM-209<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Orion<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">5060<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">I\/II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">ODM-209, a CYP 11A1 inhibitor in patients with mCRPC: Results from the STESIDES phase 1 study.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Median treatment duration &plusmn; AR-LBD mutation: 4.8 and 3.7 months<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Ten patients with mCRPC achieved a PSA reduction of &ge;50%, and 12 achieved a PSA reduction of &ge;30%<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; 18.8% achieved a partial response<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; ODM-209 was well tolerated<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">ARV-766<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Arvinas<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">5011<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">I\/II<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">ARV-766, a proteolysis targeting chimera (PROTAC) androgen receptor (AR) degrader, in metastatic castration-resistant prostate cancer (mCRPC): Initial results of a phase 1\/2 study.<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; ARV-766 showed promising clinical activity (PSA50 of 43%) in patients with tumors harboring AR LBD mutations<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; ARV-766 was well tolerated<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; No dose-limiting toxicity<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Maximum tolerated dose was not reached in Phase I (part A)<\/span><\/p>\n<\/td>\n<\/tr>\n<tr style=\"height: 0pt;\">\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">JNJ-69086420&nbsp;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">(JNJ-6420)<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">Johnson &amp; Johnson<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">5010<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">I<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">A phase 1 study of JNJ-69086420 (JNJ-6420), an actinium-225 (225Ac) -labeled antibody targeting human kallikrein 2 (hK2), for metastatic castration-resistant prostate cancer (mCRPC).<\/span><\/p>\n<\/td>\n<td style=\"vertical-align: top; background-color: #f5f5f5; padding: 5pt 5pt 5pt 5pt; overflow: hidden; overflow-wrap: break-word; border: solid #000000 1pt;\">\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Durable biochemical responses in metastatic CRPC<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Confirmed PSA50 response: 44%<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; PSA90 response of 9%;<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; ORR: 18%<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Disease control rate at 6 months: 28%<\/span><\/p>\n<p dir=\"ltr\" style=\"line-height: 1.2; margin-top: 0pt; margin-bottom: 0pt;\"><span style=\"font-size: 11pt; font-family: Calibri, sans-serif; background-color: transparent; font-variant-numeric: normal; font-variant-east-asian: normal; font-variant-alternates: normal; font-variant-position: normal; vertical-align: baseline; white-space-collapse: preserve;\">&#8211; Thrombocytopenia and ILD were TEAEs<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<span id=\"docs-internal-guid-804d4534-7fff-17d5-e609-83eb6eed4da3\"><\/span><\/div>\n\n\n\n<div style=\"height:20px\" aria-hidden=\"true\" class=\"wp-block-spacer\"><\/div>\n\n\n\n<p><strong><em>Get an exclusive <\/em><\/strong><a href=\"https:\/\/www.delveinsight.com\/asco-conference-2024\"><strong><em>ASCO 2024 Conference analysis<\/em><\/strong><\/a><strong><em> of all the abstracts presented during the conference<\/em><\/strong><\/p>\n\n\n\n<h2 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Final_Thoughts_on_Prostate_Cancer\"><\/span><strong>Final Thoughts on Prostate Cancer<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h2>\n\n\n\n<p>Prostate cancer is a significant health concern that affects millions of men and their families, but it doesn&#8217;t have to define their lives. Awareness and education are our most powerful tools in this battle. Each year, Prostate Cancer Awareness Month serves as a critical reminder that understanding the disease and taking proactive steps can lead to better outcomes.<\/p>\n\n\n\n<p>As we recognize Prostate Cancer Awareness Month, let\u2019s commit to taking action. Advocate for regular screenings, support those affected, and continue to educate ourselves and our communities. Together, we can build a future where prostate cancer is detected early, treated effectively, and eventually, significantly reduced.<\/p>\n\n\n\n<p>This September, let\u2019s stand united in the fight against prostate cancer. It\u2019s time to turn awareness into action\u2014because every conversation, every screening, and every shared story can make a difference. Don\u2019t wait\u2014reach out, educate yourself, and encourage the men in your life to do the same. Early detection is not just a slogan; it\u2019s a lifeline.<\/p>\n\n\n\n<figure class=\"wp-block-image size-large\"><a href=\"https:\/\/www.delveinsight.com\/report-store\/prostate-cancer-market-insight\"><img decoding=\"async\" width=\"1024\" height=\"194\" src=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130646\/Prostate-Cancer-Market-Outlook-1024x194.png\" alt=\"Prostate Cancer Market Outlook\" class=\"wp-image-29760\" srcset=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130646\/Prostate-Cancer-Market-Outlook-1024x194.png 1024w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130646\/Prostate-Cancer-Market-Outlook-300x57.png 300w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130646\/Prostate-Cancer-Market-Outlook-150x28.png 150w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130646\/Prostate-Cancer-Market-Outlook-768x145.png 768w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130646\/Prostate-Cancer-Market-Outlook-1536x291.png 1536w, https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130646\/Prostate-Cancer-Market-Outlook.png 1584w\" sizes=\"(max-width: 1024px) 100vw, 1024px\" \/><\/a><\/figure>\n","protected":false},"excerpt":{"rendered":"<p>Every September, the spotlight turns to prostate cancer. Prostate cancer stands as one of the most prevalent cancers among men, affecting approximately 1 in 8 men in the United States during their lifetime. With nearly 288,000 new cases diagnosed each year, men must prioritize regular screenings and early detection. The survival rates for prostate cancer [&hellip;]<\/p>\n","protected":false},"author":14,"featured_media":29757,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[17],"tags":[18946,20616,19175,399,21474,498,18412,13055,18411,20408],"industry":[17225],"therapeutic_areas":[17557,17228],"class_list":["post-29755","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-articles","tag-mcrpc","tag-mcrpc-patients","tag-mcspc","tag-metastatic-prostate-cancer","tag-nmcspc","tag-prostate-cancer","tag-prostate-cancer-epidemiological-analysis","tag-prostate-cancer-market","tag-prostate-cancer-market-size","tag-prostate-cancer-pipeline-insights","industry-pharmaceutical","therapeutic_areas-male-health","therapeutic_areas-oncology"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>September Spotlight: Prostate Cancer Awareness Month<\/title>\n<meta name=\"description\" content=\"Every September, the spotlight turns to prostate cancer. Prostate cancer stands as one of the most prevalent cancers among men.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"September Spotlight: Prostate Cancer Awareness Month\" \/>\n<meta property=\"og:description\" content=\"Every September, the spotlight turns to prostate cancer. Prostate cancer stands as one of the most prevalent cancers among men.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2024-09-25T11:20:52+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-10-10T11:48:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130517\/prostate-cancer-awareness-month.png\" \/>\n\t<meta property=\"og:image:width\" content=\"466\" \/>\n\t<meta property=\"og:image:height\" content=\"284\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Sandeep Joshi\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Sandeep Joshi\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"15 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"September Spotlight: Prostate Cancer Awareness Month","description":"Every September, the spotlight turns to prostate cancer. Prostate cancer stands as one of the most prevalent cancers among men.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month","og_locale":"en_US","og_type":"article","og_title":"September Spotlight: Prostate Cancer Awareness Month","og_description":"Every September, the spotlight turns to prostate cancer. Prostate cancer stands as one of the most prevalent cancers among men.","og_url":"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2024-09-25T11:20:52+00:00","article_modified_time":"2024-10-10T11:48:01+00:00","og_image":[{"width":466,"height":284,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130517\/prostate-cancer-awareness-month.png","type":"image\/png"}],"author":"Sandeep Joshi","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"Sandeep Joshi","Est. reading time":"15 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month","url":"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month","name":"September Spotlight: Prostate Cancer Awareness Month","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130517\/prostate-cancer-awareness-month.png","datePublished":"2024-09-25T11:20:52+00:00","dateModified":"2024-10-10T11:48:01+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a"},"description":"Every September, the spotlight turns to prostate cancer. Prostate cancer stands as one of the most prevalent cancers among men.","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/prostate-cancer-awareness-month#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130517\/prostate-cancer-awareness-month.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130517\/prostate-cancer-awareness-month.png","width":466,"height":284,"caption":"prostate-cancer-awareness-month"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/f1eefd8dd4afdb0617d6166f8b301e0a","name":"Sandeep Joshi","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7676451175fe155887a18ffb50e674b270d87436a3fc34ca206f86921cddf4cd?s=96&d=mm&r=g","caption":"Sandeep Joshi"},"sameAs":["http:\/\/Delveinsight.com"]}]}},"author_meta":{"display_name":"Sandeep Joshi","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/sjoshidelveinsight-com"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2024\/09\/25130517\/prostate-cancer-awareness-month-300x183.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Articles<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Articles<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">mCRPC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">mCRPC Patients<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">mCSPC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Metastatic Prostate Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">nmCSPC<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Prostate Cancer<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Prostate Cancer Epidemiological Analysis<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Prostate Cancer Market<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Prostate Cancer Market Size<\/a>","<a href=\"https:\/\/www.delveinsight.com\/blog\/articles\/\" class=\"advgb-post-tax-term\">Prostate cancer Pipeline Insights<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">mCRPC<\/span>","<span class=\"advgb-post-tax-term\">mCRPC Patients<\/span>","<span class=\"advgb-post-tax-term\">mCSPC<\/span>","<span class=\"advgb-post-tax-term\">Metastatic Prostate Cancer<\/span>","<span class=\"advgb-post-tax-term\">nmCSPC<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer Epidemiological Analysis<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer Market<\/span>","<span class=\"advgb-post-tax-term\">Prostate Cancer Market Size<\/span>","<span class=\"advgb-post-tax-term\">Prostate cancer Pipeline Insights<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 2 years ago","modified":"Updated 2 years ago"},"absolute_dates":{"created":"Posted on Sep 25, 2024","modified":"Updated on Oct 10, 2024"},"absolute_dates_time":{"created":"Posted on Sep 25, 2024 4:50 pm","modified":"Updated on Oct 10, 2024 5:18 pm"},"featured_img_caption":"prostate-cancer-awareness-month","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29755","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=29755"}],"version-history":[{"count":4,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29755\/revisions"}],"predecessor-version":[{"id":29974,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/29755\/revisions\/29974"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/29757"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=29755"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=29755"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=29755"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=29755"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=29755"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}